10-K · March 10, 2026
vTv is a late-stage biotech focused on an oral, liver‑selective glucokinase activator, cadisegliatin (TTP399). The company resumed its Phase 3 CATT1 trial in May 2025 (150 patients; 1:1:1 randomization, 50 per arm)…
Earnings analysis · 10-Q
VTVT earnings analysis
Filed May 13, 2026 · Our reading of the company's report
The latest report
vTv Therapeutics reported first-quarter results for 2026 with significant revenue generation of $36.8 million, a stark increase from no revenue in the prior year. The company also recorded a net income of $24.1 million,…
Read full summary
vTv Therapeutics reported first-quarter results for 2026 with significant revenue generation of $36.8 million, a stark increase from no revenue in the prior year. The company also recorded a net income of $24.1 million, reversing last year's loss and demonstrating strong growth momentum. Management remains optimistic about ongoing clinical trials and future revenue potential from its drug candidates.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.65
What stood out
-
Substantial Revenue Growth
Revenue for Q1 2026 was $36.8 million, compared to $0 in Q1 2025, marking a significant increase.
-
Positive EPS Shift
Diluted EPS for Q1 2026 was $1.65, a significant turnaround from a loss of $0.77 in Q1 2025.
-
Operating Income Growth
Operating income improved to $23.3 million in Q1 2026, up from a loss of $6.5 million in Q1 2025.
-
Increased R&D Investment
R&D expenses rose to $9.0 million in Q1 2026, up 217.2% from $2.8 million in Q1 2025.
-
Strong Cash Position
As of March 31, 2026, cash and cash equivalents totaled $98.1 million.
-
Increased Interest Income
Interest income in Q1 2026 was $0.8 million, up from $0.3 million in Q1 2025.
What to watch
-
Clinical Trial Risks
The success of pivotal trials for cadisegliatin remains uncertain, with lengthy timelines and regulatory hurdles.
-
Dependence on Cadisegliatin
The company's future revenue is highly dependent on the success of cadisegliatin, limiting diversification.
-
Need for Additional Capital
vTv anticipates needing substantial additional funding to continue clinical trials and operations.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · May 15, 2025
vTv reported no revenue for Q1 2025 and a net loss attributable to vTv Therapeutics Inc. of $5,092 (three months ended March 31, 2025), or $(0.77) per share, versus net loss $4,865 and $(1.17) per share in Q1 2024. Cash…
10-Q · August 8, 2024
vTv reported Q2 results showing no revenue for the quarter and a narrowing loss: net loss attributable to vTv was $(5,180) for the three months ended June 30, 2024 (versus $(5,619) in Q2 2023) and net loss per Class A…
10-Q · May 9, 2024
vTv reported Q1 2024 revenue of $1,000,000 (first quarter with revenue vs $0 prior year) and GAAP net loss attributable to vTv Therapeutics Inc. of $4,865,000 (EPS $(1.17)). Cash increased materially to $52,255,000 at…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.